Taburnaemine H






Names

    • Taburnaemine H

Attributes

  • Canonical SMILES

    OC[C@@]1(C(OC)=O)[C@@](CC2=C([C@@H](C3=CC=C4C(C(CCN(C5)[C@]6([H])[C@@]7(C(OC)=O)C[C@@]5([H])C[C@]6([H])CC)=C7N4)=C3)C[C@]/81[H])NC9=C2C=CC=C9)([H])N(C)CC8=C\C

  • InChI

    InChI=1S/C43H52N4O5/c1-6-25-16-24-20-42(40(49)51-4)38-29(14-15-47(21-24)39(25)42)31-17-27(12-13-35(31)45-38)30-18-33-26(7-2)22-46(3)36(43(33,23-48)41(50)52-5)19-32-28-10-8-9-11-34(28)44-37(30)32/h7-13,17,24-25,30,33,36,39,44-45,48H,6,14-16,18-23H2,1-5H3/b26-7-/t24-,25+,30-,33-,36+,39+,42-,43+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 110.88999999999997
  • #RotBonds: 5
  • MW: 704.912
  • HBD: 3
  • HBA: 7
  • logP: 5.842800000000006
  • Chemical Formula: C43H52N4O5


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Taburnaemines A-I, Cytotoxic Vobasinyl-Iboga-Type Bisindole Alkaloids from Tabernaemontana corymbosa. J Nat Prod, 2018 (PMID 29319316).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antiproliferative

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.99
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney 17.2
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 3016.36
    Distribution Blood-Brain Barrier (Central Nervous System) -3.72
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.25
    Plasma Protein Binding 90.5
    Steady State Volume of Distribution 4.7
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 11.27
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -73.85
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.44
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 5.61
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -5472336.57
    Rat (Acute) 2.82
    Rat (Chronic Oral) 2.37
    Fathead Minnow 6909.42
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 611935.02
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.92
    Log(P) 5.27
    Log S -5.76
    Log(Vapor Pressure) -20078.2
    Melting Point 280.13
    pKa Acid -107.32
    pKa Basic 4.97